Senhwa Biosciences, Inc.
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is i… Read more
Market Cap & Net Worth: Senhwa Biosciences, Inc. (6492)
Senhwa Biosciences, Inc. (TWO:6492) has a market capitalization of $14.58K (NT$482.55K) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #44385 globally and #1966 in its home market, demonstrating a -6.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Senhwa Biosciences, Inc.'s stock price NT$49.15 by its total outstanding shares 9818 (9.82K).
Senhwa Biosciences, Inc. Market Cap History: 2025 to 2026
Senhwa Biosciences, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $13.06K to $14.58K (0.00% CAGR).
Senhwa Biosciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Senhwa Biosciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6492 by Market Capitalization
Companies near Senhwa Biosciences, Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Senhwa Biosciences, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Senhwa Biosciences, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Senhwa Biosciences, Inc.'s market cap moved from $13.06K to $ 14.58K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$14.58K | +11.70% |
| 2025 | NT$13.06K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Senhwa Biosciences, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.58K USD |
| MoneyControl | $14.58K USD |
| MarketWatch | $14.58K USD |
| marketcap.company | $14.58K USD |
| Reuters | $14.58K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.